Market Cap 2.16B
Revenue (ttm) 2.20B
Net Income (ttm) -713.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 5.83
Profit Margin -32.45%
Debt to Equity Ratio 0.55
Volume 1,810,700
Avg Vol 3,130,674
Day's Range N/A - N/A
Shares Out 105.63M
Stochastic %K 23%
Beta 0.27
Analysts Sell
Price Target $22.33

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
maxmemax
maxmemax Sep. 13 at 8:31 AM
$SRPT "Huntingtons kids" Ages eligible for study in INSIGHTT: 21 Years to 70 Years Thank you for your expert opinion
0 · Reply
REDWIR
REDWIR Sep. 13 at 12:46 AM
$SRPT is this a sleeping giant or just slowed down on growth now it’s based ?
0 · Reply
Thaigrlsrk
Thaigrlsrk Sep. 13 at 12:21 AM
$SRPT WMS wants late breakers to be a surprise, they don't put them on the site map untill a few days before the conference. I don't know if a company or person accepted is allowed to announce it before that. If i remember correctly when sarepta had one before they did. That was a while ago. They have had three that i remember.
1 · Reply
Thaigrlsrk
Thaigrlsrk Sep. 13 at 12:16 AM
$SRPT I don't want to get too hopeful about Monday s chat, but we are in the window where a lot of big news is coming due.
1 · Reply
Retter7
Retter7 Sep. 12 at 11:57 PM
$SRPT I believe retail investors view $SRPT as an attractive acquisition target because it offers buyers an approved gene therapy, established DMD revenue, and a commercial-stage genetic medicine platform.
1 · Reply
et1000
et1000 Sep. 11 at 11:44 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $IFRX $DIS $TQQQ $SRPT *)
0 · Reply
TokyoJoeWasMyFriend
TokyoJoeWasMyFriend Sep. 11 at 8:15 PM
$SRPT $XBI $SPY Incredible amount of accumulation in Sarepta. Monday $MS conference and later this month the Japan 🇯🇵 Muscular Conference. Chart is 🚀
0 · Reply
FELIXE
FELIXE Sep. 11 at 6:20 PM
$SRPT something very odd with this today, I’m betting news after hours or Monday morning and could even be a buyout.
5 · Reply
fpak
fpak Sep. 11 at 5:48 PM
$SRPT Closing at $20.50
0 · Reply
gnr8nrg
gnr8nrg Sep. 11 at 4:43 PM
$SRPT Added to my Jan 2028 calls for the same 13 I sold my June 2027 calls for yesterday. I actually expect the stock to go back down to 16-18 but with yesterdays dip and today the pop not holding I'll just enjoy a rotation of 6 months for the same price to keep the gains. FED has me thinking they should do a rate hike but who knows if drug companies fall hard on that as they are usually seen as defensive. Still got some dry powder but just spent 4.5K replacing my Prius C engine and 12 volt battery. Rather keep a paid off car than add monthly car and insurance payments. Gives me more to play here long term. lol
1 · Reply
Latest News on SRPT
Sarepta price target lowered to $35 from $37 at Oppenheimer

2026-08-06T12:28:03.000Z - 5 weeks ago

Sarepta price target lowered to $35 from $37 at Oppenheimer


Sarepta reports Q2 adjusted EPS 64c, consensus 49c

2026-08-05T21:00:42.000Z - 5 weeks ago

Sarepta reports Q2 adjusted EPS 64c, consensus 49c


Sarepta Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

Sarepta Therapeutics Earnings Call Transcript: Q2 2026


Sarepta Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

Sarepta Therapeutics Quarterly report: Q2 2026


Sarepta Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

Sarepta Therapeutics Earnings release: Q2 2026


Sarepta Therapeutics Slides: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

Sarepta Therapeutics Slides: Q2 2026


Sarepta names former Abbvie president as CEO as Ingram retires

Jul 27, 2026, 9:19 AM EDT - 6 weeks ago

Sarepta names former Abbvie president as CEO as Ingram retires


Sarepta appoints Severino as Chief Executive Officer

2026-07-27T12:35:41.000Z - 6 weeks ago

Sarepta appoints Severino as Chief Executive Officer


Sarepta price target lowered to $20 from $23 at Piper Sandler

2026-07-09T11:15:12.000Z - 2 months ago

Sarepta price target lowered to $20 from $23 at Piper Sandler


Sarepta Therapeutics Transcript: AGM 2026

Jun 4, 2026, 10:00 AM EDT - 3 months ago

Sarepta Therapeutics Transcript: AGM 2026


Sarepta price target lowered to $19 from $20 at Evercore ISI

2026-05-15T12:30:23.000Z - 4 months ago

Sarepta price target lowered to $19 from $20 at Evercore ISI


Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026


Sarepta Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Sarepta Therapeutics Quarterly report: Q1 2026


Sarepta Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Sarepta Therapeutics Earnings release: Q1 2026


Sarepta Therapeutics Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Sarepta Therapeutics Slides: Q1 2026


Sarepta Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Sarepta Therapeutics Proxy statement: Proxy filing


Sarepta Therapeutics Transcript: Study result

Mar 25, 2026, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics Transcript: Study result


Sarepta Therapeutics Press release: Study result

Mar 25, 2026, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics Press release: Study result


Sarepta Therapeutics Slides: Study result

Mar 25, 2026, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics Slides: Study result


Sarepta Therapeutics CEO Ingram to retire by year end

Feb 26, 2026, 5:05 AM EST - 6 months ago

Sarepta Therapeutics CEO Ingram to retire by year end


Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025


Sarepta Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Annual report: Q4 2025


Sarepta Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Earnings release: Q4 2025


Sarepta Therapeutics Slides: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Slides: Q4 2025


Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Transcript: Study result


Sarepta Therapeutics Press release: Study result

Jan 26, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Press release: Study result


Sarepta Therapeutics Slides: Study result

Jan 26, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Slides: Study result


Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 6:20 AM EST - 10 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.


Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025


Sarepta Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Quarterly report: Q3 2025


Sarepta Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Earnings release: Q3 2025


Sarepta Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Sarepta Therapeutics Slides: Q3 2025


Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 10 months ago

Sarepta's Duchenne gene therapy misses main goal in study


maxmemax
maxmemax Sep. 13 at 8:31 AM
$SRPT "Huntingtons kids" Ages eligible for study in INSIGHTT: 21 Years to 70 Years Thank you for your expert opinion
0 · Reply
REDWIR
REDWIR Sep. 13 at 12:46 AM
$SRPT is this a sleeping giant or just slowed down on growth now it’s based ?
0 · Reply
Thaigrlsrk
Thaigrlsrk Sep. 13 at 12:21 AM
$SRPT WMS wants late breakers to be a surprise, they don't put them on the site map untill a few days before the conference. I don't know if a company or person accepted is allowed to announce it before that. If i remember correctly when sarepta had one before they did. That was a while ago. They have had three that i remember.
1 · Reply
Thaigrlsrk
Thaigrlsrk Sep. 13 at 12:16 AM
$SRPT I don't want to get too hopeful about Monday s chat, but we are in the window where a lot of big news is coming due.
1 · Reply
Retter7
Retter7 Sep. 12 at 11:57 PM
$SRPT I believe retail investors view $SRPT as an attractive acquisition target because it offers buyers an approved gene therapy, established DMD revenue, and a commercial-stage genetic medicine platform.
1 · Reply
et1000
et1000 Sep. 11 at 11:44 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $IFRX $DIS $TQQQ $SRPT *)
0 · Reply
TokyoJoeWasMyFriend
TokyoJoeWasMyFriend Sep. 11 at 8:15 PM
$SRPT $XBI $SPY Incredible amount of accumulation in Sarepta. Monday $MS conference and later this month the Japan 🇯🇵 Muscular Conference. Chart is 🚀
0 · Reply
FELIXE
FELIXE Sep. 11 at 6:20 PM
$SRPT something very odd with this today, I’m betting news after hours or Monday morning and could even be a buyout.
5 · Reply
fpak
fpak Sep. 11 at 5:48 PM
$SRPT Closing at $20.50
0 · Reply
gnr8nrg
gnr8nrg Sep. 11 at 4:43 PM
$SRPT Added to my Jan 2028 calls for the same 13 I sold my June 2027 calls for yesterday. I actually expect the stock to go back down to 16-18 but with yesterdays dip and today the pop not holding I'll just enjoy a rotation of 6 months for the same price to keep the gains. FED has me thinking they should do a rate hike but who knows if drug companies fall hard on that as they are usually seen as defensive. Still got some dry powder but just spent 4.5K replacing my Prius C engine and 12 volt battery. Rather keep a paid off car than add monthly car and insurance payments. Gives me more to play here long term. lol
1 · Reply
BeardBird
BeardBird Sep. 11 at 3:22 PM
$SRPT Weekly chart showing bullish signs
0 · Reply
Valueforall
Valueforall Sep. 11 at 3:18 PM
$SRPT Must read article if you are heavily invested here and feeling your weekend is coming and your mind is not on hugging you kids / grandkids/ dog or yourself but on your accounts. Investors in this particular ticker remind me of my $BAND and $ARWR and $MRNABETS just to name a few. investing in small biotech requires the need and desire to embrace uncomfortable situations. The feelings of torture, dismay and depression are all positive signs in today’s algo trading world. We have seen it time and time again but we have poor short term memories and forget the lessons. Enjoy and desire the need to bend over and get jacked in the a$SHOLE. It means goodness is around the corner. 😌 btw. No margin please 🙏. Makes the above very difficult to see play out. I sold band this past year from $50’s to $70’s. Every time I bought the mudhaphukka at $13 I imagined I was getting an immediate $30 return (my most conservative base case)
2 · Reply
FELIXE
FELIXE Sep. 11 at 3:17 PM
$SRPT very odd action today , would not be surprised to see news after hours or Monday pre market.
0 · Reply
Winston_Churchill
Winston_Churchill Sep. 11 at 3:14 PM
$SRPT This couldn’t possibly remain in the $20’s for the remainder of 2026….. right?
1 · Reply
fpak
fpak Sep. 11 at 2:58 PM
$SRPT F you Michael!!
0 · Reply
DeportedGreta
DeportedGreta Sep. 11 at 2:43 PM
$SRPT pos
1 · Reply
Thaigrlsrk
Thaigrlsrk Sep. 11 at 2:08 PM
$SRPT I hope MS gives a glimer of how far along dosing is in the sirolimus trial on Monday. It is IMO the most important thing going on . It 's key to a double at least in revenues, an indicator of the younger kids on the label, necessary for LGMD2e BLA, and precorser to LGMD native protein drugs being partnerd.
0 · Reply
Thaigrlsrk
Thaigrlsrk Sep. 11 at 1:46 PM
$SRPT Many on here have stated Sarepta will be bought of course that may happen but not until the sirolimus data indicates Non ambs will be back and not until ,DM1, FSHD and Huntingtons appear approvable. Sarepta wont be undersold it just ain't in the cards.JMO.
1 · Reply
Thaigrlsrk
Thaigrlsrk Sep. 11 at 10:46 AM
$SRPT If Sarepta made the cut ( or has the data) for a WMS poster Late breaker (They) should know by today. More them likely so should the big shorts.
1 · Reply
Valueforall
Valueforall Sep. 11 at 8:28 AM
$SRPT Just listened to offspring… ‘Got to keep em sa-ra-peta……! Hey, hey!……don’t pay no……your under 18 you won’t be doing anytime 🎶 Got keep em sa-ra-peta!!! If that isn’t a bullish sign on why not to buy the dip well then….
1 · Reply
7990E
7990E Sep. 10 at 8:33 PM
$SRPT well it looks like the gains from 19-22+ were short covering. 27 million to now 24.6 million shares short. Not a lot but is a good thing.
1 · Reply
Kylea1
Kylea1 Sep. 10 at 8:02 PM
$SRPT $OCUL volatility trades
0 · Reply